EcoDrugPlus

Methionyl Aminopeptidase 2

Ensembl ID : ENSAPEG00000022182
Gene Symbol: METAP2
2 Cross references
229 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSAPEG00000018577
Gene Symbol: MAPK1
1 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSAPEG00000017981
Gene Symbol: MAPK10
1 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSAPEG00000002863
Gene Symbol: MAPK11
1 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSAPEG00000019544
Gene Symbol: MAPK14
1 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSAPEG00000005804
Gene Symbol: MAPK14
1 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSAPEG00000015004
Gene Symbol: MAPK3
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSAPEG00000016602
Gene Symbol: MAPK8A
2 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSAPEG00000021730
Gene Symbol: MAPK8B
1 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSAPEG00000017164
Gene Symbol: MAPK9
1 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSAPEG00000020723
Gene Symbol: MAP2K1
1 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2a

Ensembl ID : ENSAPEG00000006964
Gene Symbol: MAP2K2A
1 Cross references
218 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).